Investing in iosBio: Shaping the Future of Vaccination

iosBio presents a compelling investment opportunity

Our primary investment focus is advancing OraPro-EBV, our first-in-class oral vaccine candidate targeting the significant unmet need and $12.6bn market opportunity in Epstein-Barr Virus.

 

 

 

We are currently seeking £12-30 million in Series B funding to advance OraPro-EBV through Phase 1/2 clinical trials and scale our operations.

 

 

Why Invest?

Large Unmet Need & Market Opportunity (EBV)

Proprietary, Differentiated Multi-Platform Technology (Oral, Thermostable, ESD™, AI)

Outstanding Preclinical Data for Lead Candidate

Demonstrated *in vivo* Platform Protection

Experienced Leadership & Development Team

Clear Clinical and Regulatory Pathway

Significant Global Health Impact Potential

Accredited investors may request access to our confidential investor deck.

Request Investor Deck

Stay informed on our progress.

View latest news

For investment enquiries, please contact:

Wayne Channon, Executive Chairman | wayne@iosbio.com | +44-7930-419941

Wayne Channon, Executive Chairman

wayne@iosbio.com

+44-7930-419941

Follow us

Keep up to date with our news and find out more about investment opportunities with iosBio.

The team of doctors and scientists at iosBio believe that the next great leap forward in immunization will be oral delivery

Enabling the fastest and most cost-effective deployment of vaccines the world has ever seen. This is not just a huge leap forward from a humanitarian perspective, oral vaccine technology also represents a significant commercial opportunity.

Contact us on

info@iosbio.com / 01444 241911

or fill out the form below.





    We will not, in any circumstances share your personal information with other individuals or organizations without your permission.